---
url: https://endpoints.news/sanofis-phase-3-eczema-data-cloud-hopes-for-potential-immunology-blockbuster/?u=786c1a58-a68e-4805-8b2a-95166d105077&s=email&c=79153abc-b363b558-d07ec2fd&utm_medium=email&utm_campaign=2372%20-%20Sanofis%20next%20big%20immunology%20hope%20reports%20mixed%20results%20Insider&utm_content=2372%20-%20Sanofis%20next%20big%20immunology%20hope%20reports%20mixed%20results%20Insider+CID_450019cb41a3a3367729b3c579615714&utm_source=ENDPOINTS%20emails&utm_term=Sanofis%20Phase%203%20eczema%20data%20cloud%20hopes%20for%20potential%20immunology%20blockbuster
title: "Sanofi’s Phase 3 eczema data cloud hopes for potential immunology blockbuster"
clipped: 2026-01-23 13:02
source: browser-history
---

# Sanofi’s Phase 3 eczema data cloud hopes for potential immunology blockbuster

> Source: [https://endpoints.news/sanofis-phase-3-eczema-data-cloud-hopes-for-potential-immunology-blockbuster/?u=786c1a58-a68e-4805-8b2a-95166d105077&s=email&c=79153abc-b363b558-d07ec2fd&utm_medium=email&utm_campaign=2372%20-%20Sanofis%20next%20big%20immunology%20hope%20reports%20mixed%20results%20Insider&utm_content=2372%20-%20Sanofis%20next%20big%20immunology%20hope%20reports%20mixed%20results%20Insider+CID_450019cb41a3a3367729b3c579615714&utm_source=ENDPOINTS%20emails&utm_term=Sanofis%20Phase%203%20eczema%20data%20cloud%20hopes%20for%20potential%20immunology%20blockbuster](https://endpoints.news/sanofis-phase-3-eczema-data-cloud-hopes-for-potential-immunology-blockbuster/?u=786c1a58-a68e-4805-8b2a-95166d105077&s=email&c=79153abc-b363b558-d07ec2fd&utm_medium=email&utm_campaign=2372%20-%20Sanofis%20next%20big%20immunology%20hope%20reports%20mixed%20results%20Insider&utm_content=2372%20-%20Sanofis%20next%20big%20immunology%20hope%20reports%20mixed%20results%20Insider+CID_450019cb41a3a3367729b3c579615714&utm_source=ENDPOINTS%20emails&utm_term=Sanofis%20Phase%203%20eczema%20data%20cloud%20hopes%20for%20potential%20immunology%20blockbuster)

January 23, 2026 10:39 AM EST

[R&D](https://endpoints.news/channel/rd/ "Channel: R&D")

[Pharma](https://endpoints.news/channel/pharma/ "Channel: Pharma")

# Sanofi's Phase 3 eczema da­ta cloud hopes for po­ten­tial im­munol­o­gy block­buster

### [Max Gelman](https://endpoints.news/author/max-gelman/ "See all stories by Max Gelman")

#### Senior Editor

The cen­ter­piece of Sanofi’s im­munol­o­gy ef­forts [suc­ceed­ed](https://www.globenewswire.com/news-release/2025/09/04/3144170/0/en/Press-Release-Sanofi-s-amlitelimab-met-all-primary-and-key-secondary-endpoints-in-the-COAST-1-phase-3-study-in-adults-and-adolescents-with-atopic-dermatitis.html) in two more Phase 3 eczema stud­ies in the US, the com­pa­ny an­nounced Fri­day …

![Endpoints News](https://endpoints.news/wp-content/themes/endpoints-rakia/assets/svg/epn_logo.svg)

### Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

[SIGN UP](https://profile.endpoints.news/sso?mode=sign-up&r=https%3A%2F%2Fendpoints.news%2Fauth&a%5Bt%5D=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)
[LOG IN](https://profile.endpoints.news/sso?r=https%3A%2F%2Fendpoints.news%2Fauth&a%5Bt%5D=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)
[BECOME A PREMIUM SUBSCRIBER](https://profile.endpoints.news/upgrade)